Skip to main content
. Author manuscript; available in PMC: 2007 Jun 30.
Published in final edited form as: Auton Neurosci. 2006 May 2;126-127:380–389. doi: 10.1016/j.autneu.2006.02.030

Figure 4.

Figure 4

Fluorescence images of fractalkine expression in urinary bladder sections of control (A), 4 hr (B), 48 hr (C) and chronic (D) CYP treated rats. For all images, exposure times were held constant and all tissues were processed simultaneously. In control and 4 hr CYP treated rats, little if any fractalkine expression was visible in the urothelium (u; A, B) but some diffuse fractalkine-immunoreactivity was visible in the lamina propria (lp; B). CYP treatment (48 hr, C; chronic, D) upregulated expression of fractalkine in the urothelium in all layers (apical, intermediate and basal) of the urothelium. Calibration bar represents 50 μm.